Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children

被引:0
|
作者
Erazmus, Michal [1 ]
Ruminska, Malgorzata [1 ]
Witkowska-Sedek, Ewelina [1 ]
Kucharska, Anna M. [1 ]
Stelmaszczyk-Emmel, Anna [2 ]
Majcher, Anna [1 ]
Pyrzak, Beata [1 ]
机构
[1] Med Univ Warsaw, Dept Paediat & Endocrinol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Lab Diagnost & Clin Immunol Dev Age, Warsaw, Poland
来源
关键词
sRANKL; OPG; sRANKL ratio; cardiovascular risk factors; obesity; children; LOW SERUM-LEVELS; INSULIN-RESISTANCE; RANK LIGAND; URIC-ACID; VASCULAR CALCIFICATION; METABOLIC SYNDROME; RISK-FACTORS; B LIGAND; OSTEOPROTEGERIN; ATHEROSCLEROSIS;
D O I
10.3389/fendo.2022.963467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionChildhood obesity contributes to the development of cardiovascular diseases. The molecular pathway - receptor activator of nuclear factor-kappa beta ligand (RANKL), its receptor RANK and osteoprotegerin (OPG) - takes part not only in bone metabolism but is also involved in the atherosclerosis process. RANKL stimulates osteogenic differentiation and calcification of vascular smooth cells. The associations between the OPG-sRANKL system and various cardiovascular risk factors were displayed. We aimed to evaluate the relationships between serum sRANKL (soluble RANKL) levels and the OPG/sRANKL ratio with cardiometabolic risk factors in overweight and obese children. Material and methodsThe study included 70 children with overweight and obesity (mean age 13.0 +/- 2.8) and 35 age-matched normal weight, healthy peers as a control group. In all patients, anthropometric measurements and laboratory tests were performed. Additionally, an oral glucose tolerance test (OGTT) was made only in overweight and obese children. Atherogenic and insulin resistance indices were calculated. ResultsOverweight and obese children had lower sRANKL levels compared to the control group (median 276.95 vs 325.90, p=0.011), and consequently a higher OPG/sRANKL ratio (0.02 vs 0.01, p = 0.013). The studied children in the lowest quartile of sRANKL levels had higher body weight, Body Mass Index, waist circumference and increased glucose and insulin levels 60 minutes after OGTT and higher uric acid values compared to children in the highest quartile. In multivariable linear regression analysis sRANKL negatively correlated only with uric acid (beta = - 0.508, p = 0.041). No association was found for the OPG/sRANKL ratio. ConclusionExcess fat mass seems to alter the OPG/RANKL ratio mainly by reducing serum sRANKL levels. The correlation between sRANKL and uric acid may suggest a contribution of the OPG-sRANKL system in the cardiometabolic process, but that observation should be confirmed in future studies.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-κB ligand in postmenopausal obese women
    Ostrowska, Zofia
    Swietochowska, Elzbieta
    Marek, Bogdan
    Kajdaniuk, Dariusz
    Tyrpien-Golder, Krystyna
    Wolkowska-Pokrywa, Kinga
    Damasiewicz-Bodzek, Aleksandra
    Kos-Kudla, Beata
    ENDOKRYNOLOGIA POLSKA, 2014, 65 (06) : 438 - 448
  • [22] LMS-based continuous pediatric reference values for soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin (OPG) in the HARP cohort
    Tietze, Helene
    Pott, Veronika
    Kanzelmeyer, Nele
    Memaran, Nima
    Baumann, Ulrich
    Mindermann, Charlotte
    Suhlrie, Adriana
    Drube, Jens
    Melk, Anette
    Das, Anibh M.
    Schnabel, Dirk
    Haffner, Dieter
    Leifheit-Nestler, Maren
    OSTEOPOROSIS INTERNATIONAL, 2024, 35 (03) : 533 - 542
  • [23] Osteoprotegerin and Ligand of Receptor Activator of Nuclear Factor
    Tan, Lijun
    Ren, Yijin
    Wang, Jun
    Jiang, Lingyong
    Cheng, Hui
    Sandham, Andrew
    Zhao, Zhihe
    ANGLE ORTHODONTIST, 2009, 79 (02) : 292 - 298
  • [24] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Lorenz C. Hofbauer
    Armin E. Heufelder
    Journal of Molecular Medicine, 2001, 79 : 243 - 253
  • [25] Osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in the serum of healthy adults
    Jung, K
    Lein, M
    Von Hösslin, K
    Grosse, A
    Roth, S
    Possinger, K
    Lüftner, D
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (03): : 177 - 181
  • [26] Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
    Granchi, D
    Garaventa, A
    Amato, I
    Paolucci, P
    Baldini, N
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (01) : 146 - 151
  • [27] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Hofbauer, LC
    Heufelder, AE
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6): : 243 - 253
  • [28] Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand
    Yamamoto, Yohei
    Udagawa, Nobuyuki
    Matsuura, Sachiko
    Nakamichi, Yuko
    Horiuchi, Hiroshi
    Hosoya, Akihiro
    Nakamura, Midori
    Ozawa, Hidehiro
    Takaoka, Kunio
    Penninger, Josef M.
    Noguchi, Toshihide
    Takahashi, Naoyuki
    ENDOCRINOLOGY, 2006, 147 (07) : 3366 - 3374
  • [29] Multimerization of the receptor activator of nuclear factor-κB ligand (RANKL) isoforms and regulation of osteoclastogenesis
    Ikeda, T
    Kasai, M
    Suzuki, J
    Kuroyama, H
    Seki, S
    Utsuyama, M
    Hirokawa, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (47) : 47217 - 47222
  • [30] Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media
    Kuczkowski, Jerzy
    Sakowicz-Burkiewicz, Monika
    Izycka-Swieszewska, Ewa
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2010, 31 (06) : 404 - 409